Identifying Circulating Exosomes as a Biomarker in Glioma

Article
Conference|American Association for Cancer Research Annual Meeting (AACR)

In this video, Michael Ciesielski, PhD, of Roswell Park Cancer Institute in Buffalo, talks about circulating exosomes isolated from the serum of malignant glioma patients enrolled in a completed phase I clinical trial of an anti-survivin vaccine (SurVaxM).

Dr. Ciesielski presented a study on how specific exosomes appear to be associated with early tumor progression in recurrent malignant glioma patients at the 2017 American Society for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

Recent Videos
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Related Content
Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

FDA Approves Mirdametinib in Adult/Pediatric NF1-PN

Russ Conroy
February 11th 2025
Article

Findings from the phase 2b ReNeu trial support the approval of mirdametinib for patients with neurofibromatosis type 1-associated plexiform neurofibromas.

The Stand Up 2 Cancer Colorectal Dream Team

The Stand Up 2 Cancer Colorectal Dream Team

Luis A. Diaz, Jr., MD
May 10th 2018
Podcast

During AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.

FDA Grants Priority Review to Mirdametinib in Adult/Pediatric NF1-PN

FDA Grants Priority Review to Mirdametinib in Adult/Pediatric NF1-PN

Ariana Pelosci
August 28th 2024
Article

A PDUFA date has been set for February 28, 2025, for the potential approval of mirdametinib in neurofibromatosis type 1-associated plexiform neurofibromas.

Uncovering Epigenetic Targets in Cancer

Uncovering Epigenetic Targets in Cancer

Stephen Baylin, MD
April 11th 2018
Podcast

Dr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Novel CAR T-Cell Therapy Yields Response in R/R Non-Hodgkin Lymphoma

Kyle Doherty
April 14th 2024
Article

HR001 was found to have an efficacious response for patients with relapsed/refractory non-Hodgkin lymphoma.

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Response Observed With Savolitinib Combo in EGFR, MET, Osimertinib-Resistant NSCLC

Courtney Flaherty
April 13th 2024
Article

A proteogenomic analysis found savolitinib plus osimertinib elicited a response in patients with EGFR-mutated, MET-amplified advanced NSCLC.